Securities code: 688277 securities abbreviation: Tinavi Medical Technologies Co.Ltd(688277) Announcement No.: 2021-074 Tinavi Medical Technologies Co.Ltd(688277)
Announcement on updating the reply to the third round examination and inquiry letter on the application documents for issuing shares to specific objects by Beijing Tinavi Medical Technologies Co.Ltd(688277) Medical Technology Co., Ltd
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law. Tinavi Medical Technologies Co.Ltd(688277) (hereinafter referred to as “the company”) received the third round of examination and inquiry letter on Tinavi Medical Technologies Co.Ltd(688277) application documents for issuing shares to specific objects (szkss (refinancing) [2021] No. 100) (hereinafter collectively referred to as “examination and inquiry letter”) issued by Shanghai Stock Exchange (hereinafter referred to as “Shanghai Stock Exchange”) on November 16, 2021.
The company and relevant intermediaries have carefully studied and implemented the problems listed in the audit inquiry letter one by one, and explained, demonstrated and analyzed the relevant problems according to the requirements of the audit inquiry letter, For details, please refer to the relevant documents disclosed by the company on the website of Shanghai Stock Exchange (www.sse. Com.. CN) on November 26, 2021. Now, in combination with the company’s revision of the plan for issuing A-Shares to specific objects, the company has supplemented and modified some contents in the reply to the above audit inquiry letter together with relevant intermediaries. For details, please refer to the “about Tinavi Medical Technologies Co.Ltd(688277) disclosed by the company on the same day Reply to the third round of examination and inquiry letter of application documents for issuing shares to specific objects (Revised Version) and other relevant documents.
The issue of shares by the company to specific objects needs to be reviewed by Shanghai Stock Exchange, And obtained the approval of China Securities Regulatory Commission (hereinafter referred to as “CSRC”) ）It can be implemented only after the decision of consent to registration is made. Whether it can finally pass the examination of Shanghai Stock Exchange and obtain the decision of consent to registration from CSRC and its time are still uncertain. According to the progress of the matter, the company will timely perform the obligation of information disclosure in strict accordance with the provisions and requirements of relevant laws and regulations. Please pay attention to the investment risks.
It is hereby announced.
Tinavi Medical Technologies Co.Ltd(688277) board of directors December 24, 2021
